Botox for Crow's Feet!

On September 11, the U.S. Food and Drug Administration (FDA) approved a use of Botox® Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe lateral canthal lines, which are more commonly referred to as "crow's feet."  Physicians have used Botox® in this area for years "off-label," but the new FDA approval will offer consumers an additional level of confidence in the safety and efficacy of the product.   

Botox® Cosmetic was first approved in 2002 for treatment of glabellar lines (frown lines between the eyebrows).  The FDA has also stated that both frown lines and crow’s feet can be treated at the same time.

The FDA approval is based on two clinical efficacy and safety studies:

“The studies enrolled 833 adult participants with moderate to severe lateral canthal lines who were randomly assigned to receive Botox or placebo. Results showed that those treated with Botox had greater improvement compared to placebo in the appearance of lateral canthal lines.

The most common adverse reaction associated with the use of Botox Cosmetic for treatment of lateral canthal lines is eyelid edema, a condition in which the eyelids are swollen and contain excessive fluid.” (1)

Botox^® is one of our most popular noninvasive cosmetic procedures for both women and men.  It is a purified protein that works by blocking nerve impulses, allowing muscles to relax, effectively eliminating wrinkles and giving the face a rejuvenated look.  Using a small needle, tiny injections are made into the muscles that cause frown lines.  Within days you may see an improvement, but it can take two weeks to see the full effect.  Typically Botox® treatment lasts three to four months.

Dermatology Associates of Rochester is also a member of the Brilliant Distinctions® Program, which is a program Allergan (the company who makes Botox®) created to allow you to get exclusive offers on Botox® Cosmetic and their other products including the cosmetic filler, Juvederm®.

Reference:

(1) http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm367662.htm